Entrada Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 04, 2023 / 01:00PM GMT
Debjit Chattopadhyay - Guggenheim Partners - Analyst

Good morning and welcome to day two of Guggenheim's Genomic Medicine Rare Disease conference. This is our fifth edition. My name is Debjit, and I'm one of the therapeutic analysts at Guggenheim. My privilege to host Dipal Doshi -- Doshi is CEO of Entrada -- and Natarajan Sethuraman, Chief Scientific Officer. Thank you and good morning and welcome to you both.

Dipal Doshi - Entrada Therapeutics, Inc. - President & CEO

Thanks, Debjith. Great to be here, and thanks for giving us the opportunity to present the Entrada story.

Questions and Answers:

Debjit Chattopadhyay - Guggenheim Partners - Analyst

Great. So, maybe we could just get started on your EEV platform and how this approach might be superior in partitioning to the target relative to the other delivery approaches in neuromuscular diseases?

Dipal Doshi - Entrada Therapeutics, Inc. - President & CEO

Sure. Yeah. I can start and of course, Natarajan and I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot